![Andreas Jurgeit](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andreas Jurgeit
Directeur/Membre du Conseil chez
Mediar Therapeutics, Inc.
Profil
Andreas Jurgeit is currently Director at ImmunOs Therapeutics AG since 2022, Director at Mediar Therapeutics, Inc., Partner at Gimv Nederland BV since 2021, and Partner at Lundbeckfonden Emerge since 2018.
Former roles include Director at Indi Molecular, Inc., Director at Merck Ventures BV from 2016 to 2018, Investment Advisor at Redalpine Venture Partners AG in 2014, and Partner at Gimv NV.
Education includes graduate studies at the University of Innsbruck and a doctorate from the University of Zurich.
Postes actifs de Andreas Jurgeit
| Sociétés | Poste | Début |
|---|---|---|
Lundbeckfonden Emerge
 Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge is an active manager which provides equity funding for seed and early-stage capital requirements, and provides management support. The firm targets startups operating in health technology sector, industries such as pharmaceuticals. Lundbeckfonden Emerge invests in companies located in Denmark, and looks to take minority stake positions in its investment | Private Equity Investor | 07/12/2018 |
ImmunOs Therapeutics AG
 ImmunOs Therapeutics AG BiotechnologyHealth Technology Engages in discovering and developing novel human immunomodulatory proteins | Directeur/Membre du Conseil | 07/06/2022 |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to halt and reverse fibrotic | Directeur/Membre du Conseil | - |
Gimv Nederland BV
 Gimv Nederland BV Investment ManagersFinance Gimv-Nederland is a small- and medium-sized buyout specialist focused on Germany, the Netherlands and Belgium. They are an active, long-term manager which targets profitable medium-sized manufacturing, service and trading companies with good market positions. They focus on companies with positive earnings and sales of EUR 20-200 million, aiming to increase the investee company's value over the long-term. In addition to providing equity capital, the firm partners with investee management, providing advice and expertise as a majority or minority shareholder. They also provide growth capital in later rounds of financing until the portfolio company is self-financed or ready for an IPO. Gimv-Nederland's investments consist primarily of MBOs which involve expansion financing, ownership succession, business division spin-offs or other changes in shareholder structure. Gimv-NI's investment managers commit some of their personal capital to every investment. | Private Equity Investor | 01/04/2021 |
Anciens postes connus de Andreas Jurgeit
| Sociétés | Poste | Fin |
|---|---|---|
Indi Molecular, Inc.
 Indi Molecular, Inc. BiotechnologyHealth Technology Develops a synthetic class of diagnostic and therapeutic agents | Directeur/Membre du Conseil | 01/12/2018 |
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures invests in companies located in the Netherlands. The firm targets companies operating in the fields of healthcare, healthcare drug development, life science tools, electronics and frontier technology & sustainability sectors. It provides financing for early stage capital requirements. | Private Equity Investor | 01/12/2018 |
Redalpine Venture Partners AG
 Redalpine Venture Partners AG Investment ManagersFinance Redalpine invests in companies located across Europe. The firm focuses on a broad range of sectors and industries. It provides financing for early stage capital requirements. | Analyste en capital-investissement | 31/12/2014 |
| GIMV NV | Private Equity Investor | - |
Formation de Andreas Jurgeit
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Gimv NV
 Gimv NV Investment ManagersFinance Acts as a private equity and venture capital firm | Finance |
Gimv Nederland BV
Gimv Nederland BV Investment ManagersFinance Gimv-Nederland is a small- and medium-sized buyout specialist focused on Germany, the Netherlands and Belgium. They are an active, long-term manager which targets profitable medium-sized manufacturing, service and trading companies with good market positions. They focus on companies with positive earnings and sales of EUR 20-200 million, aiming to increase the investee company's value over the long-term. In addition to providing equity capital, the firm partners with investee management, providing advice and expertise as a majority or minority shareholder. They also provide growth capital in later rounds of financing until the portfolio company is self-financed or ready for an IPO. Gimv-Nederland's investments consist primarily of MBOs which involve expansion financing, ownership succession, business division spin-offs or other changes in shareholder structure. Gimv-NI's investment managers commit some of their personal capital to every investment. | Finance |
University of Innsbruck
 University of Innsbruck Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Zurich
 University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Redalpine Venture Partners AG
Redalpine Venture Partners AG Investment ManagersFinance Redalpine invests in companies located across Europe. The firm focuses on a broad range of sectors and industries. It provides financing for early stage capital requirements. | Finance |
Indi Molecular, Inc.
Indi Molecular, Inc. BiotechnologyHealth Technology Develops a synthetic class of diagnostic and therapeutic agents | Health Technology |
Lundbeckfonden Emerge
Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge is an active manager which provides equity funding for seed and early-stage capital requirements, and provides management support. The firm targets startups operating in health technology sector, industries such as pharmaceuticals. Lundbeckfonden Emerge invests in companies located in Denmark, and looks to take minority stake positions in its investment | Finance |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures invests in companies located in the Netherlands. The firm targets companies operating in the fields of healthcare, healthcare drug development, life science tools, electronics and frontier technology & sustainability sectors. It provides financing for early stage capital requirements. | Finance |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology Engages in discovering and developing novel human immunomodulatory proteins | Health Technology |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to halt and reverse fibrotic | Health Technology |
